Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 24, Issue 135, 2015, Pages 58-64

  Cottin, Vincent ^a   Maher, Toby ^b,c  

^a UNIVERSITÉ LYON 1   (France)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; SUNSCREEN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANOREXIA; CAUSE OF DEATH; CLINICAL PRACTICE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXPERIENCE; FIBROSING ALVEOLITIS; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; SKIN MANIFESTATION; SUN EXPOSURE; VOMITING; IDIOPATHIC PULMONARY FIBROSIS; REGISTER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; REGISTRIES;

EID: 84923876116     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00011514     Document Type: Review

References (21)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
3. Annex I. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf Date last updated: October 2014. Date last accessed: January 20, 2015.
4. U.S. Food and Drug Administration. FDA approves Esbriet to treat idiopathic pulmonary fibrosis. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm Date last updated: October 15, 2014. Date last accessed: January 20, 2015.
5. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20: 85–97.
6. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821–829.
7. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
8. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
9. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014: 19: 740–748.
10. Costabel U, Albera C, Cohen A, et al. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension studyj. Eur Respir J| 2011; 38: Suppl. 55, 174s.
11. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198–205.
12. Koschel D, Cottin V, Skold M, et al. Pirfenidone post-authorisation safety registry (PASSPORT)–Interim analysis of IPF treatment. Eur Respir J 2014; 44: Suppl. 58, 1904.
13. Wijsenbeek MS, Van Beek FT, Geel AL, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. Am J Respir Crit Care Med 2013; 187: A4340.
14. Ravaglia C, Gurioli C, Romagnoli M. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series. Eur Respir J 2013; 42: Suppl. 57, 3370.
15. Nieto Barbero MA, Valenzuela C, Rivera Ortega P. Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP). Eur Respir J 2013; 42: Suppl. 57, 2361.
16. Bonella F, Wessendorf TE, Costabel U. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Dtsch med Wochenschr 2013; 138: 518–523.
17. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431–1437.
18. Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Resp Invest 2014; 52: 136–143.
19. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199–207.
20. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Resp Med 2014; 108: 224–226.
21. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31: 375–391.